GlassScriptPhysician profile
Roberta J Backel
NPI 1851571467
$3,865.56
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,226 · 2022: $907 · 2023: $1,033 · 2024: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,732.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $919.63 | 2021-2024 | |
| Novo Nordisk INC | $724.58 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $238.57 | 2021-2024 | Zepbound |
| Amgen INC. | $207.86 | 2021-2024 | Repatha, Otezla, Evenity |
| Intra-Sana Laboratories | $200.00 | 2023 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Pfizer INC. | $187.81 | 2021-2024 | |
| Amarin Pharma, INC. | $184.93 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $175.03 | 2021-2024 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $123.78 | 2022-2023 | |
| Abbott Laboratories | $96.35 | 2021-2023 | Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $90.84 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.23 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $83.66 | 2022-2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.83 | 2023 | Xifaxan, Relistor |
| Shield Therapeutics INC | $72.45 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $61.63 | 2022 | |
| Currax Pharmaceuticals LLC | $61.60 | 2023-2024 | Contrave |
| Novartis Pharmaceuticals Corporation | $50.12 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $43.36 | 2021 | |
| Eisai INC. | $39.11 | 2021 | |
| Glaxosmithkline, LLC. | $25.17 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.53 | 2024 | Caplyta |
| Scilex Pharmaceuticals INC. | $19.02 | 2024 | |
| Optinose US, INC. | $16.11 | 2021 | |
| Lundbeck LLC | $15.77 | 2024 | Rexulti |
| Astellas Pharma US INC | $14.04 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.33 | 2021 | |
| Adlon Therapeutics L.P. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Backel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.